Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in... Leukemia & Lymphoma, January 2015; 56(1): 226–229 © 2014 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2014.910657 LETTER TO THE EDITOR Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies 1 1 1 2 1 James M. Bogenberger , Devora Delman , Nanna Hansen , Riccardo Valdez , Veena Fauble , 1 1 Ruben A. Mesa & Raoul Tibes 1 2 Department of Hematology and Oncology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA Novel targeted therapies for the treatment of acute myeloid at low nM doses of ABT-737 and ABT-199, mostly in the leukemia (AML) and other advanced myeloid malignan- range of 40 – 160 nM for both compounds, doses which most cies are urgently needed. Recently we reported results from frequently corresponded to maximal synergy. Th e respec- in vitro studies comparing the BCL-2, BCL-X and BCL-w tive 5-Aza concentrations shown in Figure 1 are 10 – 15% inhibitor ABT-737 (preclinical compound with similar inhib- maximal eff ective concentration (EC ) doses for AML 10 – 15 itory profi le to ABT-263/navitoclax) with the selective BCL-2 samples and EC doses for MDS/CMML samples, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Leukemia & Lymphoma Taylor & Francis

Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

4 pages

Loading next page...
 
/lp/taylor-francis/ex-vivo-activity-of-bcl-2-family-inhibitors-abt-199-and-abt-737-dsx05w70jA

References (14)

Publisher
Taylor & Francis
Copyright
© 2014 Informa UK, Ltd.
ISSN
1029-2403
eISSN
1042-8194
DOI
10.3109/10428194.2014.910657
pmid
24707940
Publisher site
See Article on Publisher Site

Abstract

Leukemia & Lymphoma, January 2015; 56(1): 226–229 © 2014 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2014.910657 LETTER TO THE EDITOR Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies 1 1 1 2 1 James M. Bogenberger , Devora Delman , Nanna Hansen , Riccardo Valdez , Veena Fauble , 1 1 Ruben A. Mesa & Raoul Tibes 1 2 Department of Hematology and Oncology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA Novel targeted therapies for the treatment of acute myeloid at low nM doses of ABT-737 and ABT-199, mostly in the leukemia (AML) and other advanced myeloid malignan- range of 40 – 160 nM for both compounds, doses which most cies are urgently needed. Recently we reported results from frequently corresponded to maximal synergy. Th e respec- in vitro studies comparing the BCL-2, BCL-X and BCL-w tive 5-Aza concentrations shown in Figure 1 are 10 – 15% inhibitor ABT-737 (preclinical compound with similar inhib- maximal eff ective concentration (EC ) doses for AML 10 – 15 itory profi le to ABT-263/navitoclax) with the selective BCL-2 samples and EC doses for MDS/CMML samples,

Journal

Leukemia & LymphomaTaylor & Francis

Published: Jan 2, 2015

There are no references for this article.